PREVAIL (NCT05202509)

Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies (PREVAIL)

PI: Alexander Postalian, MD

Sponsor: New Amsterdam

ENROLLMENT COMPLETE

Eligibility Requirements

1. Males and females ≥ 18 years age
2. Established ASCVD including:

– Coronary artery disease
– Cerebrovascular disease
– Peripheral Artery disease

3. On maximally tolerated lipid-modifying therapy
4. Fasting LDL-C ≥ 55 mg/dL
5. Fasting triglycerides < 400 mg/dL
6. Estimated glomerular filtration rate ≥ 30 mL/min

PREVAIL Participant Flyer

PREVAIL Brochure